Chargement de l’entreprise
Keep exploring
The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
EXELExelixis, Inc.16,8B $USA+
JAZZJazz Pharmaceuticals plc15,5B $USA
TECHBIO-Techne Corp11,4B $USA+
HALOHalozyme Therapeutics, Inc.11,4B $USA+
TGTXTG Therapeutics, Inc.9,7B $USA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Sales of cancer medicines98 %
Les parts du chiffre d'affaires sont des estimations pour Q1 2026, pas des chiffres tirés d'un document officiel.
En concurrence avec
Ce qu'elle vend6
BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.
Afficher 3 de plus
XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.
Qui l'achète2
- Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
- Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
- 2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
- 3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
- 4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.
Ce qui pourrait mal tourner
- 1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
- 2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
- 3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.
À propos de Beone Medicines Ltd.
BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.
- Siège
- Basel, Switzerland
- Fondée en
- 2010
- Effectif
- More than 12,000 (Q2 2026, medium)
- Cotée sur
- Nasdaq
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Beone Medicines Ltd. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
